Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

BACKGROUND: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Springerplus
Auteurs principaux: Seno, Takahiro, Yamamoto, Aihiro, Kukida, Yuji, Hirano, Aiko, Kida, Takashi, Nakabayashi, Amane, Fujioka, Kazuki, Nagahara, Hidetake, Fujii, Wataru, Murakami, Ken, Oda, Ryo, Fujiwara, Hiroyoshi, Kohno, Masataka, Kawahito, Yutaka
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2016
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://ncbi.nlm.nih.gov/pubmed/27462504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-2704-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires